# Duchenne muscular dystrophy

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/duchenne-muscular-dystrophy
Canonical HTML page: https://getbiobrief.com/entity/duchenne-muscular-dystrophy

## Timeline

- **2026-03-11**: Initial Inquiry — The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
- **2026-03-10**: Commissioner Meeting — Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.

## Recent coverage (1 stories)

### GOP Senator Probes FDA Over Rare Disease Drug Rejections
2026-03-10 22:18:47 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
Full story: https://getbiobrief.com/story/ron-johnson-fda-rare-disease-investigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.